Ticagrelor monotherapy: When is mono‐antiplatelet therapy (MAPT) equivalent or better?
Sign Up to like & getrecommendations! Published in 2020 at "Catheterization and Cardiovascular Interventions"
DOI: 10.1002/ccd.29411
Abstract: Ischemic and bleeding events portend equivalently poor prognosis after percutaneous coronary intervention (PCI). Risk factors for these untoward events largely overlap limiting the “decoupling” of bleeding and ischemic risk. While individual patient risk scores inform… read more here.
Keywords: ticagrelor monotherapy; risk; antiplatelet therapy; bleeding ... See more keywords
Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of the American College of Cardiology"
DOI: 10.1016/j.jacc.2019.08.997
Abstract: BACKGROUND Data on optimal antiplatelet treatment regimens in patients who undergo multivessel percutaneous coronary intervention (PCI) are sparse. OBJECTIVES This post hoc study investigated the impact of an experimental strategy (1-month dual antiplatelet therapy [DAPT]… read more here.
Keywords: ticagrelor monotherapy; pci; multivessel pci; month ... See more keywords
Commentary: Ticagrelor monotherapy—Not for CABG?
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Cardiac Surgery"
DOI: 10.1111/jocs.16203
Abstract: Saphenous vein grafts (SVGs) remain the most commonly used conduits in coronary artery bypass grafting (CABG) despite greater rates of both early and late occlusion compared to arterial grafts. In a recent meta‐analysis based on… read more here.
Keywords: trial; ticagrelor monotherapy; cabg; ticagrelor ... See more keywords